
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD is viewed positively because its direct-to-patient telehealth model lowers friction for consumers facing long wait times and provider shortages, while its integrated pharmacy, care center, and AI-enabled infrastructure create a scalable, one-stop healthcare platform. Growth is being reinforced by high-demand categories: about 108,000 weight management subscribers at end-2Q26, 356,000 active subscribers, 95% of new weight-management patients starting branded GLP-1s, and women’s health patient growth of 134% sequentially with a projected $3M-$5M quarterly revenue run rate in 4Q26. The AT&T collaboration could materially expand reach without added acquisition cost by tapping 29 million eligible customers initially and more than 100 million nationwide over time, while rising insurance coverage and early Medicare adoption add additional upside.
Bears say
LifeMD is facing a weaker fundamental setup because 2Q26 revenue of $47.3M fell 4% year over year and missed expectations, while adjusted EBITDA of ($3.5M) and a net loss of $7.9M showed profitability remains pressured. Management lowered FY2026 revenue guidance to $205.5M-$212.5M from $220M-$230M and adjusted EBITDA to ($6M)-break-even as higher customer acquisition costs, competitive discounting, and the costly transition to branded GLP-1s weighed on results. Although weight management subscribers reached about 108,000 and total active subscribers rose 20% year over year to about 356,000, only about 8,000 new weight loss members were added in 2Q26, suggesting growth is not yet offsetting the margin drag and execution risk.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About LifeMD (LFMD) Forecast
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares